Rugby has a habit of testing the body. During a match I tore my calf — one of those injuries that normally sidelines you for weeks while the muscle fibres repair and the surrounding inflammation settles. Determined to recover as effectively as possible, I incorporated several research peptides into my recovery protocol alongside sensible rehab, mobility work, and gradual loading. My weekly protocol consisted of: 5 mg MOTS‑C 2 mg SLU‑PP‑332 5 mg combined BPC‑157 and TB‑500 These compounds are frequently discussed in research circles for their potential roles in tissue repair, mitochondrial efficiency, and endurance metabolism. Supporting Tissue Repair The combination of BPC-157 and TB-500 is commonly studied for its potential to support soft-tissue healing. In animal and laboratory studies, these peptides have shown the ability to: Promote angiogenesis (formation of new blood vessels) Support collagen organisation and tendon repair Improve blood flow to injured tissue For a calf tear, improved circulation and tissue regeneration are critical. Muscles heal by rebuilding damaged fibres and restoring connective tissue integrity. Enhanced vascularisation may help deliver oxygen, nutrients, and growth factors to the injured area more efficiently. During rehab I noticed the calf becoming less tight and more stable over the weeks, allowing progressive return to loading and movement. Improving Energy Metabolism Where the protocol became particularly interesting was the inclusion of MOTS-C. Research suggests that MOTS-C interacts with metabolic pathways that regulate mitochondrial function and glucose utilisation. Mitochondria are essentially the energy generators of muscle cells, and improved mitochondrial signalling may support: Better fat and glucose metabolism Improved exercise endurance More efficient energy production during activity In simple terms, muscles may become better at producing usable energy during effort, particularly during sustained cardiovascular work.

Stack 1 MOTS C and Reta Stack 2 Reta Stack 3 MOTS C, SLUPP and Reta

1) You can hit a “satiety ceiling,” so the difference you feel shrinks Both tirzepatide and retatrutide activate GLP-1 pathways that reduce appetite via gut–brain signalling and central satiety circuits. Once someone has been on high-dose therapy, appetite and cravings may already be strongly suppressed (and eating patterns already adapted), so moving to another incretin drug may produce less noticeable incremental appetite change—even if weight loss continues. GLP-1 appetite effects are well-established and partly central (brain) and partly peripheral (GI). Translation: if hunger is already “turned down to 2/10,” it’s hard to feel a new drug turning it down further—even if metabolism is changing. 2) The “fullness” sensation from slowed gastric emptying often attenuates with time A big part of early appetite suppression on GLP-1–based therapy is slower gastric emptying (food stays in the stomach longer → earlier fullness). But multiple clinical and peri-operative reviews note that the gastric-emptying delay can attenuate with ongoing treatment (often framed as tachyphylaxis/attenuation), meaning the dramatic early “I can’t eat” feeling is less prominent later. So if someone is coming from prolonged/high-dose tirzepatide, they may: - already be adapted to the gastric-emptying effect, and - perceive retatrutide as “less appetite suppressing,” even if it’s still effective. (There is debate on how complete this attenuation is across drugs and measurement methods, but attenuation is commonly described clinically.) 3) Retatrutide’s extra weight effect isn’t only appetite — it likely adds energy expenditure via glucagon biology Retatrutide is a triple agonist (GLP-1 + GIP + glucagon receptors), unlike tirzepatide (GLP-1 + GIP). That glucagon-receptor component is important because glucagon signalling can: - increase energy expenditure/thermogenesis (context-dependent), - increase fat oxidation and shift fuel use, - counterbalance some of the metabolic “slow-down” that comes with weight loss.

Established in October 2025 Thrivepeptiva have established ourselves to be somewhat of a revolutionary force within the world of peptides by creating bespoke blends for clients to assist directly with their specific requirements.